Skip to main content
Equibles

AUROPHARMA · Aurobindo Pharma Limited · Documents

Use AUROPHARMA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AUROPHARMA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
1,829.00 INR +24.00 (+1.33%) At close · Nov 13
Rebalance outlook locked
Volume · Nov 13 221.71K Avg daily vol (14 sessions) 123K

The company's reports, filings, earnings calls and investor events, most recent first. Search these from Claude or ChatGPT →

Earnings call Q2 2027 earnings call Held Nov 5, 2026
2026
Nov 5
Earnings call
Revenue rises 24% to 10,263 crores as EBITDA grows 28%

Aurobindo Pharma reported Q2 FY27 revenue of 10,263 crores, up 24% year-on-year, and operating EBITDA of 2,156 crores, up 28%. Management reiterated FY27 guidance for double-digit revenue growth, EBITDA margins north of 21% and absolute EBITDA in excess of 8,000 crore.

5 source passages
Welcome to Aurobindo Pharma Q2 FY27 earnings call. We are pleased to report our highest ever revenue for the quarter of 10,263 crores, representing year-on-year growth of 24%. Operating EBITDA was 2,156 crores, growing at 28% year-on-year with a margin of 21%, despite increase in input cost and freight rate. FY27 guidance: We reiterate our FY guidance with the double-digit revenue growth, EBITDA margins north of 21% and absolute EBITDA in excess of 8,000 crore, with a potential upside from positive outperformance in our high-value strategic business areas. Open the document at this passage
Showing 1–3 of 3 documents